A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Objectives To assess the safety and efficacy of anlotinib (a multi‐targeted tyrosine kinase inhibitor) combined with toripalimab (a PD‐1 monoclonal antibody) in the treatment of unresectable biliary tract cancer (BTC). Methods In this prospective, single‐arm, single‐centre exploratory clinical study, patients with locally progressed or metastatic BTC were included. Patients were treated with anlotinib (12 mg, PO, QD, for 2 weeks and then stopped for a week, 21 days for a cycle) and toripalimab (240 mg, IV, Q3W). The primary endpoint of the study was the objective response rate (ORR), as defined in RECIST version 1.1 criteria. Results In this study, 15 BTC patients who met the criteria were enrolled. The ORR was 26.7%, the median progression‐free survival (mPFS) was 8.6 months (95% CI: 2.1–15.2), the median overall survival (mOS) was 14.53 months (95% CI: 0.8–28.2) and the disease control rate (DCR) was 87.6%. A patient with hilar cholangiocarcinoma was successfully converted after three cycles of treatment and underwent surgical resection. Furthermore, patient gene sequencing revealed that STK11 was mutated more frequently in patients with poor outcomes. In addition, patients with a CD8/Foxp3 ratio > 3 had a longer survival than those with a CD8/Foxp3 ratio ≤ 3 (P = 0.0397). Conclusions In patients with advanced BTC, the combination of anlotinib and toripalimab demonstrated remarkable anti‐tumor potential, with increased objective response rates (ORR), longer overall survival (OS) and progression‐free survival (PFS). Moreover, STK11 and CD8/Foxp3 may be as biomarkers that can predict the effectiveness of targeted therapy in combination with immunotherapy.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A phase II study to evaluate the safety and efficacy of anlotinib combined with toripalimab for advanced biliary tract cancer
- Date Crossref
- 01/01/2024
- Éditeur
- Wiley
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Nanjing University of Chinese Medicine Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Nanjing Traditional Chinese Medicine Hospital pays non établi dans la noticeÉtablissement de santé
-
Nanjing Drum Tower Hospital Department of Oncology pays non établi dans la noticeÉtablissement de santé
-
Nanjing Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Nanjing University Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Clinical College of Traditional Chinese and Western Medicine Department of Oncology pays non établi dans la noticeUniversité ou école supérieure
Department of Oncology — Nanjing University of Chinese Medicine, Nanjing Traditional Chinese Medicine Hospital et Department of Oncology — Nanjing Drum Tower Hospital, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.